Skip to content

In the BioHarmony Drug Report Database

Semaglutide

Ozempic, Rybelsus, Wegovy (semaglutide) is a protein pharmaceutical. Semaglutide was first approved as Ozempic on 2017-12-05. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Ozempic's patents are valid until 2038-08-24 (FDA).
Trade Name Ozempic, Rybelsus
Common Name Semaglutide
Indication diabetes mellitus, type 2 diabetes mellitus
Drug Class Peptides: GLP peptide analogs
Semaglutide
Get full access now